Skip to content
Evigrade
CriticalDirect oral anticoagulants (factor Xa inhibitors)×Direct oral anticoagulants (factor Xa inhibitors)

Updated · Methodology

Mechanism

Edoxaban and apixaban both directly and reversibly inhibit the same clotting factor, factor Xa, and reduce thrombin generation (edoxaban and apixaban summaries of product characteristics, SmPCs, European Medicines Agency, EMA). Both SmPCs contraindicate use with any other anticoagulant because of the increased risk of bleeding, and the edoxaban SmPC names apixaban (EMA). Healthy volunteers took apixaban for three days and switched to edoxaban on day 4. After the switch, their prothrombin time was the same as on day 3 of apixaban (edoxaban SmPC, EMA). This is why the first edoxaban dose after a switch can be given at the time of the next scheduled dose of the previous drug (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site. Standard coagulation tests are not suitable for monitoring the effect of edoxaban (EMA).

Management

Edoxaban is contraindicated with any other anticoagulant, except when switching from one oral anticoagulant to another. The edoxaban summary of product characteristics (SmPC) names apixaban in this contraindication (edoxaban SmPC, European Medicines Agency, EMA). The apixaban SmPC likewise contraindicates any other anticoagulant except in specific circumstances, including a switch of anticoagulant therapy (apixaban SmPC, EMA). When switching from apixaban to edoxaban, stop apixaban and start edoxaban at the time of the next scheduled apixaban dose (edoxaban SmPC, EMA). When switching from edoxaban to apixaban, stop edoxaban and start apixaban at the time of the next scheduled edoxaban dose (EMA). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, FDA). Promptly evaluate any signs of blood loss (FDA). If severe bleeding occurs, stop edoxaban. There is no specific antidote (EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Apixaban

Other interactions with Edoxaban